{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mwesigwa B"],"funding":["Intramural NIH HHS","U.S. Department of Defense","National Institutes of Health","U.S. Army"],"pagination":["1408-1417"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10837320"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(12)"],"pubmed_abstract":["<h4>Background</h4>Sudan Ebola virus can cause severe viral disease, with an average case fatality rate of 54%. A recent outbreak of Sudan Ebola virus in Uganda caused 55 deaths among 164 confirmed cases in the second half of 2022. Although vaccines and therapeutics specific for Zaire Ebola virus have been approved for use during outbreak situations, Sudan Ebola virus is an antigenically distinct virus with no approved vaccines available.<h4>Methods</h4>In this phase 1, open-label, dose-escalation trial we evaluated the safety, tolerability, and immunogenicity of a monovalent chimpanzee adenovirus 3 vaccine against Sudan Ebola virus (cAd3-EBO S) at Makerere University Walter Reed Project in Kampala, Uganda. Study participants were recruited from the Kampala metropolitan area using Internat"],"journal":["The Lancet. Infectious diseases"],"pubmed_title":["Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial."],"pmcid":["PMC10837320"],"funding_grant_id":["Z99 AI999999"],"pubmed_authors":["Kiweewa F","Musingye E","Murray T","Schech S","Cordon J","Nassaka R","O'Connell SE","Scott PT","Plummer SH","Strom L","Naluyima P","Coates EE","Ploquin A","Kibuuka H","Costner PJM","Wamala A","Gordon IJ","Amare MF","Namugabo J","RV 508 Study Team","Stein JA","Gall JG","Sullivan NJ","Wandege J","O'Callahan M","Mendoza FH","Atwijuka B","Widge AT","Dulan CNM","Beck A","McDermott AB","Ledgerwood JE","Nanyondo J","Mwesigwa B","Nakabuye I","Beingana C","Houser KV","Basappa M","Nassanga G","Mutebe H","Flach B","Andrews C","Narpala SR","Anne Eller L","Padilla M","Kityo H","Gaudinski MR","Tindikahwa A","Koup RA","Guech M","Namuli J","Swanson PA","Amoa-Awua O","Hofstetter AR","Vazquez S","Gajjala SR","Ake JA","Seo E","Nanteza C","Ssekitoleko M","Mukyala MG","Sondergaard EL","Holman LA","Kabahubya M","Saunders JG","Cox J","Kizanye J","Modjarrad K","Mascola JR","Ortega-Villa AM","Hunegnaw R","Yamshchikov GV","Lin BC","Morgan P","Happe M","Hickman SP"],"additional_accession":[]},"is_claimable":false,"name":"Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.","description":"<h4>Background</h4>Sudan Ebola virus can cause severe viral disease, with an average case fatality rate of 54%. A recent outbreak of Sudan Ebola virus in Uganda caused 55 deaths among 164 confirmed cases in the second half of 2022. Although vaccines and therapeutics specific for Zaire Ebola virus have been approved for use during outbreak situations, Sudan Ebola virus is an antigenically distinct virus with no approved vaccines available.<h4>Methods</h4>In this phase 1, open-label, dose-escalation trial we evaluated the safety, tolerability, and immunogenicity of a monovalent chimpanzee adenovirus 3 vaccine against Sudan Ebola virus (cAd3-EBO S) at Makerere University Walter Reed Project in Kampala, Uganda. Study participants were recruited from the Kampala metropolitan area using Internat","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-06-02T21:59:09.139Z","creation":"2025-04-19T14:40:14.076Z"},"accession":"S-EPMC10837320","cross_references":{"pubmed":["37544326"],"doi":["10.1016/S1473-3099(23)00344-4","10.1016/s1473-3099(23)00344-4"]}}